QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

(High)

(Neutral)

Rhea-AI Summary

QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.

The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.

QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.

Positive

Q1 2025 net sales grew 7% CER to $483 million, exceeding guidance
QuantiFERON TB test sales increased 15% CER
QIAstat-Dx system sales grew over 35% CER
Raised full-year 2025 EPS guidance to $2.35 CER from $2.28 CER
Q1 2025 adjusted EPS of $0.55 CER exceeded previous $0.50 CER outlook

Negative

Sample technologies sales declined 1% CER due to reduced Life Sciences customer spending
Expected headwinds from new U.S. import tariffs

News Market Reaction – QGEN

+5.36%

+5.36% Session move

In the trading session that priced this news, QGEN gained 5.36%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/06/2025 - 12:45 PM

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook

VENLO, THE NETHERLANDS / ACCESS Newswire / April 6, 2025 / QIAGEN N.V. (NYSE:QGEN)(Frankfurt Prime Standard:QIA) announces preliminary Q1 2025 results that exceed the outlook for both net sales and adjusted earnings per share (EPS), and also updates its adjusted EPS outlook for full-year 2025, reflecting strong performances across many growth drivers.

Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER.

Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers.

Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.

Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year.

QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
ISIN: NL0015002CX3
Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:

John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com

End of Inside Information

SOURCE: QIAGEN N.V.

View the original press release on ACCESS Newswire

FAQ

What is QIAGEN's Q1 2025 revenue growth and total sales?

QIAGEN's Q1 2025 net sales grew 5% (7% CER) to $483 million, exceeding the previous guidance of 3% CER growth.

How much did QIAGEN raise its 2025 EPS guidance?

QIAGEN raised its full-year 2025 adjusted EPS guidance to $2.35 CER from the previous $2.28 CER.

What was the growth rate of QIAGEN's QuantiFERON TB test in Q1 2025?

QIAGEN's QuantiFERON latent TB test grew approximately 15% CER in Q1 2025.

How did QIAGEN's QIAstat-Dx system perform in Q1 2025?

The QIAstat-Dx syndromic testing system grew above 35% CER, driven by respiratory, gastrointestinal, and meningitis testing.

What challenges is QIAGEN facing in 2025?

QIAGEN faces headwinds from new U.S. import tariffs and experienced a 1% CER decline in sample technologies due to cautious customer spending.